MUTYH-Associated Polyposis

With special permission from Myriad Genetics, a patient reporting a previous medical condition unrelated to colorectal cancer is recommended to undergo a genetic test for MUTYH. This genetic test can help identify individuals at increased risk for developing colorectal cancer.

If you have been told you have an increased risk of developing colorectal cancer...

How to Use This Test

Read the provided information and follow the instructions included in your test kit. Before discussing your test results with a healthcare provider, please review the information provided with insights and recommendations.

Intended Users

Telomeric DNA Test kit is intended for use by healthcare providers. This test is not intended for self-testing or patient use.

Limitations

- Use of this product is not intended for diagnosis at the point of care.
- This product is intended for molecular diagnosis of conditions.
- This product is not intended for use in newborns or pregnant women.
- This product is intended for use in patients who have been informed of the limitations and risks of the test.

Important Information

- This product is intended for use in patients who have been informed of the limitations and risks of the test.
- This product is intended for use in patients who have been informed of the limitations and risks of the test.
- This product is intended for use in patients who have been informed of the limitations and risks of the test.
- This product is intended for use in patients who have been informed of the limitations and risks of the test.
- This product is intended for use in patients who have been informed of the limitations and risks of the test.

You have an increased risk of developing colorectal cancer based on your results.

Research suggests that people with a GRRD0 variant have a 44-102% chance of developing colorectal cancer.

If you have been informed of the limitations and risks of the test, you may wish to discuss your results with a healthcare provider.

Since you share DNA with your family members, they may wish to learn more about their risk.

There are things you can do to reduce your risk for colorectal cancer.

- Eat a healthy diet
- Maintain a healthy weight
- Exercise regularly

Your healthcare provider may recommend additional steps you can take to reduce your risk for colorectal cancer.

About MUTYH-Associated Polyposis

Myriad Genetics, Inc. offers genetic testing for individuals who have been previously diagnosed with colorectal cancer. This test is not intended for use in self-testing or patient use.

It is important to discuss this result with a healthcare professional.

For further information, please visit the Myriad Genetics website or contact your healthcare provider.
Frequently Asked Questions

MTHPR-associated Polyps

What is MTHPR?
This term refers to two specific genes playing a role in the MTHPR group, namely MTHFR and C677T. These are folate receptors that influence blood folate levels and can lead to an increased risk of colorectal cancer and other gastrointestinal cancers.

What are the symptoms of MTHPR-associated polyps?
Symptoms may include abdominal pain, bloating, constipation, diarrhea, and rectal bleeding. However, these symptoms are not specific to MTHPR-associated polyps and can also be caused by other conditions. Regular screening with colonoscopies is important for early detection.

How can MTHPR be treated?
MTHPR is typically treated with lifestyle changes, such as a healthy diet rich in folate and fiber, regular exercise, and quitting smoking. Additionally, medications like aspirin may be prescribed to reduce inflammation and the risk of colorectal cancer.

What is the prognosis for MTHPR-associated polyps?
The prognosis for MTHPR-associated polyps is generally good with early detection and treatment. However, the risk of developing colorectal cancer increases with age, and regular screening is recommended.

Where can I learn more about MTHPR and associated polyps?
You can find more information on MTHPR and associated polyps at the National Cancer Institute's website. They provide comprehensive resources, including guidelines for screening and treatment. Additionally, many healthcare professionals offer educational materials on this topic.

What is the role of diet in the prevention of MTHPR-associated polyps?
A healthy diet rich in fruits, vegetables, and whole grains can help reduce the risk of developing colorectal cancer. Foods high in fiber can help maintain normal bowel function and prevent constipation, which can reduce the risk of colorectal cancer.

What are the potential side effects of treatment for MTHPR-associated polyps?
Side effects of treatment for MTHPR-associated polyps may include gastrointestinal issues such as bloating, constipation, or diarrhea. These are typically mild and can be managed with changes in diet or medication adjustments.

What is the role of surgery in the treatment of MTHPR-associated polyps?
Surgery may be recommended for certain cases where polyps are large or present in hard-to-reach areas. The surgery can help reduce the risk of colorectal cancer and improve the overall quality of life.

How does genetic counseling benefit patients with MTHPR-associated polyps?
Genetic counseling can help patients understand their risk of developing colorectal cancer and other conditions associated with MTHPR. It can also guide patients in making informed decisions about screening, prevention, and treatment options.

What are the potential risks of not seeking treatment for MTHPR-associated polyps?
If left untreated, MTHPR-associated polyps can lead to the development of colorectal cancer, which can be life-threatening. Early detection and treatment are crucial for improving outcomes and reducing the risk of complications.

What is the role of future research in the management of MTHPR-associated polyps?
Future research is essential to improve our understanding of MTHPR and associated polyps. This includes developing personalized treatment plans, improving screening methods, and identifying new therapeutic targets to enhance outcomes for patients.